Cardiovascular risk in people with Crohn's disease and ulcerative colitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational study that follows adults with Crohn's disease or ulcerative colitis and a matched control group for two years to compare the occurrence of major cardiovascular events. The researchers will examine factors that predict MACEs in IBD versus controls and will apply multi-omics analyses with artificial intelligence to identify biomarkers linked to cardiovascular risk in IBD. The aim is to improve understanding of how IBD relates to cardiovascular outcomes and to identify potential predictors beyond traditional risk scores. No intervention is being tested; the study observes real-world patient outcomes. Enrollment is at IRCCS Policlinico San Donato in Milan, Italy, with participants required to have a confirmed IBD diagnosis and to commit to 2 years of follow-up.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients with confrimed diagnosis of Crohn's disease and Ulcerative colitis-

Exclusion Criteria:

No willing to sign the informe content and have 2 years of follow-up

Where it's running

• IRCCS San Donato POliclinic
  San Donato Milanese, Milan, Italy Recruiting

Study contacts

• Principal investigator: Vito Annese, Prof — IRCCS Policlinico San Donato, Universita' Vita-Salute San Raffeele, Milano, Italy
• Study coordinator: Vito Annese, Prof.
• Email: vito.annese@grupposandonato.it
• Phone: +39 3388261812

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Atrial fibrillation screening for people with higher-than-median NT-proBNP in Tromsø

  This will test whether giving 7-day wearable ECG monitoring to people aged 40+ with NT-proBNP above the median can find atrial fibrillation and reduce ischemic stroke and vascular deaths compared with no long-term monitoring.

  Recruiting at 2 sites University Hospital of North Norway · Tromsø and 1 other locations · NCT07343895

• Integrated care for older patients with atrial fibrillation

  This study is testing a new team-based care approach for older patients with atrial fibrillation and other health issues to see if it helps them manage their condition better than regular care.

  Recruiting at 50 sites Heart Care Foundation · Haskovo and 49 other locations · NCT06775028

• AI-based assessment of heart function using ECG wearable monitors

  This study tests if a new AI tool using a wearable heart monitor can accurately check heart function in people with heart failure compared to traditional heart scans.

  Recruiting at 8 sites Peerbridge Health, Inc · Orange, California and 7 other locations · NCT06699056

• Investigating heart disease risk factors in psoriasis patients

  This study is trying to see if certain heart-related markers can help predict heart disease risk in people with psoriasis.

  Recruiting Herlev and Gentofte Hospital · Hellerup, Copenhagne · NCT04950218

• AI-powered ECG to help diagnose and predict outcomes in heart disease

  Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.

  Recruiting Inha University Hospital · Incheon, Incheon · NCT07856472

• Pace-and-ablate strategy in atrial fibrillation: who benefits and long-term outcomes

  This study looks at adults with atrial fibrillation who underwent AV node ablation with permanent pacing to see who develops pacing-induced problems and how they do long-term.

  Recruiting at 5 sites Insel Gruppe AG, University Hospital Bern · Zabrze and 4 other locations · NCT07852221

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.